Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pliant Therapeutics Inc (NASDAQ: PLRX) closed the day trading at $11.85 down -3.50% from the previous closing price of $12.28. In other words, the price has decreased by -$3.50 from its previous closing price. On the day, 0.54 million shares were traded. PLRX stock price reached its highest trading level at $12.64 during the session, while it also had its lowest trading level at $11.79.
Ratios:
For a better understanding of PLRX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.47 and its Current Ratio is at 14.47. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on December 08, 2023, initiated with a Overweight rating and assigned the stock a target price of $41.
On May 18, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $48.
On April 13, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $44.Robert W. Baird initiated its Outperform rating on April 13, 2023, with a $44 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jul 10 ’24 when Coulie Bernard sold 38,710 shares for $11.56 per share. The transaction valued at 447,488 led to the insider holds 482,936 shares of the business.
Lefebvre Eric sold 12,319 shares of PLRX for $142,408 on Jul 10 ’24. The Chief Medical Officer now owns 213,052 shares after completing the transaction at $11.56 per share. On Jul 10 ’24, another insider, Cummings Keith Lamont, who serves as the Chief Financial Officer of the company, sold 10,911 shares for $11.56 each. As a result, the insider received 126,131 and left with 282,115 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PLRX now has a Market Capitalization of 720496640 and an Enterprise Value of 344115872.
Stock Price History:
Over the past 52 weeks, PLRX has reached a high of $19.88, while it has fallen to a 52-week low of $10.29. The 50-Day Moving Average of the stock is -1.74%, while the 200-Day Moving Average is calculated to be -17.97%.
Shares Statistics:
Over the past 3-months, PLRX traded about 626.97K shares per day on average, while over the past 10 days, PLRX traded about 487260 shares per day. A total of 59.92M shares are outstanding, with a floating share count of 53.31M. Insiders hold about 12.32% of the company’s shares, while institutions hold 100.43% stake in the company. Shares short for PLRX as of 1721001600 were 6958605 with a Short Ratio of 11.23, compared to 1718323200 on 6608888. Therefore, it implies a Short% of Shares Outstanding of 6958605 and a Short% of Float of 11.790000000000001.
